Table 2 Non-BCMA-targeted CAR-T clinical trials in multiple myeloma
From: Chimeric antigen receptor T cell therapies for multiple myeloma
Trial site/company | Target | No. of patients | Costimulatory domain | Conditioning | Study design | Efficacy | Safety | Registration number/reference |
|---|---|---|---|---|---|---|---|---|
University of Pennsylvania, Novartis | CD19 | 10 | 4-1BB | HDM + ASCT | 5 × 107 CAR+T cells | ORR, 20% (2 of 10) | Mild CRS | NCT02135406 [41] |
Baylor University | Kappa LC | 7 | CD28 | CP or none | 1.7 × 107–1.9 × 108 CAR+T cells/m2 | 4 SD | Mild CRS | NCT00881920 [47] |
General Hospital of PLA, China | CD138 | 5 | CD28 | PCD, CP, or VAD | 22-90 × 107 CAR+T cells | 4 SD. | Mild CRS | NCT01886976 [73] |
Single-center phase 1 study/Dana-Farber Cancer Institute | NKG2DL | 5 | Dap10 | None | 1–30 × 106 CAR+T cells | ORR, 0% (0 of 5) | Mild CRS | NCT02203825 [86] |